TYPHIM VI INJECTION 0.025 MG/0.5 ML [SIN08481P]
Active ingredients: PURIFIED VI CAPSULAR POLYSACCHARIDE OF S.TYPHI (TYPE 2 STRAIN)
Last updated on 9 October 2026
Product Info
TYPHIM VI INJECTION 0.025 MG/0.5 ML
[SIN08481P]
Product information
Active Ingredient and Strength | PURIFIED VI CAPSULAR POLYSACCHARIDE OF S.TYPHI (TYPE 2 STRAIN) - 25 MICROGRAMS |
Dosage Form | INJECTION |
Manufacturer and Country | SANOFI WINTHROP INDUSTRIE - FRANCE |
Registration Number | SIN08481P |
Licence Holder | SANOFI-AVENTIS SINGAPORE PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J07AP03 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
4.1 Therapeutic indications
Prevention of typhoid fever in adults and in children over 2 years of age, and especially: travellers to endemic areas, migrants, health care professionals and military personnel.
Dosing
4.2 Posology and method of administration
Posology
RESTRICTED TO ADULTS AND CHILDREN OVER 2 YEARS OF AGE.
A single injection of 0.5 mL. If exposure to risk continues and depending on the level of exposure, revaccination will be performed every 2–3 years.
Paediatric population
The vaccination schedule is the same for children and for adults.
Method of administration
Intramuscular or subcutaneous route
Contraindications
4.3 Contraindications
Hypersensitivity to the active substance, to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information to formaldehyde or to casein (which may be present as traces in each dose, owing to their use during the manufacturing process).
Vaccination should be postponed in case of acute febrile disease.